| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.25 | 1e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.19 | 0.0003 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.17 | 0.0006 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.12 | 0.03 |